Quantiferon TB gold-plus assays (reagents and controls) for the detection of mycobacterium tuberculosis.
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- W81K0225DA026
- Awardee
-
Qiagen, LLC UEI W2GLKC92ZH73
- Awarding agency
-
Defense Health Agency
Department of Defense
- Task orders
- 2 $97,179 obligated
Award facts
- Opportunity
-
- Reagents for detection of Mycobacterium Tuberculosis: Liaison QuantiFERON TB Gold Plus and LIAISON Control QuantiFERON TB Gold Plus Pre-Solicitation · W81K0225QA107 · Posted Aug 21, 2025
- Combined order value
- $194,358 Current and potential, with all options
- Last date to order 20% complete
- IDV ceiling 20% used
- $489,895.00
- Maximum order
- $97,179.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The Defense Health Agency awarded a single-award indefinite delivery contract to Qiagen, LLC on November 1, 2025, for QuantiFERON TB Gold-Plus assays, reagents, and controls for the detection of Mycobacterium tuberculosis, with a ceiling value of $489,895 and ultimate completion date of September 30, 2030. No set-aside applies.
Performance occurs in Germantown, Maryland. The contract stems from market research conducted by the Medical Readiness Contracting Office—Pacific at Joint Base Lewis McChord, which identified Qiagen as the FDA-approved source for in-house latent TB testing using Interferon Gamma Release technology. Madigan Army Medical Center's Department of Pathology requires these reagents for tuberculosis detection using existing LIAISON XL System equipment.
Two delivery orders have been issued under this IDIQ. The Defense Health Agency issued a delivery order on October 1, 2025, with a ceiling of $97,179 and completion date of September 30, 2026, for QuantiFERON TB Gold-Plus assays and controls on a firm fixed price basis, performed in Germantown, Maryland. A subsequent delivery order issued on October 1, 2026, carries a ceiling of $97,179 with completion date September 30, 2027.
NAICS code 325413 (In-Vitro Diagnostic Substance Manufacturing) and PSC code 6550 (In Vitro Diagnostic Substances, Reagents, Test Kits and Sets) apply.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract W81K0225DA026?
W81K0225DA026 was awarded to Qiagen, LLC by Defense Health Agency (Department of Defense) on November 1, 2025.
How much is contract W81K0225DA026 worth?
Orders under W81K0225DA026 have obligated $97,179. Their combined current value, with exercised options, is $194,358. W81K0225DA026's own ceiling is $489,895. A single order can be worth up to $97,179.
How many orders have been placed under contract W81K0225DA026?
2 orders have been placed under W81K0225DA026, the latest on October 1, 2026.
Who can order from contract W81K0225DA026?
W81K0225DA026 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract W81K0225DA026 competed?
The extent of competition for W81K0225DA026 was not competed under sap. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV